Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
Authors
Keywords
-
Journal
CANCER
Volume 117, Issue 23, Pages 5351-5358
Publisher
Wiley
Online
2011-05-17
DOI
10.1002/cncr.26188
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combining Bevacizumab with Temozolomide Increases the Antitumor Efficacy of Temozolomide in a Human Glioblastoma Orthotopic Xenograft Model
- (2015) Véronique Mathieu et al. NEOPLASIA
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
- (2010) Albert Lai et al. JOURNAL OF CLINICAL ONCOLOGY
- Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma
- (2010) Richard M. Zuniga et al. JOURNAL OF NEURO-ONCOLOGY
- Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
- (2009) D A Reardon et al. BRITISH JOURNAL OF CANCER
- Phase II Trial of Irinotecan and Carboplatin for Extensive or Relapsed Small-Cell Lung Cancer
- (2009) Gigi Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of salvage reirradiation for malignant gliomas that progress on bevacizumab
- (2009) Roy G. Torcuator et al. JOURNAL OF NEURO-ONCOLOGY
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
- (2009) Eudocia C. Quant et al. NEURO-ONCOLOGY
- Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
- (2009) F. M. Iwamoto et al. NEUROLOGY
- FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme
- (2009) M. H. Cohen et al. ONCOLOGIST
- Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme
- (2008) Jeannette R. Flynn et al. CANCER
- Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial
- (2008) Andreas Hermes et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
- (2008) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results
- (2008) Marta Santisteban et al. JOURNAL OF NEURO-ONCOLOGY
- Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
- (2008) Kathleen R. Lamborn et al. NEURO-ONCOLOGY
- Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model
- (2008) Kristoph Jahnke et al. NEURO-ONCOLOGY
- Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
- (2008) A. D. Norden et al. NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search